Show simple item record

dc.contributor.authorHussain, SA
dc.contributor.authorAnsari, J
dc.contributor.authorHuddart, R
dc.contributor.authorPower, DG
dc.contributor.authorLyons, J
dc.contributor.authorWylie, J
dc.contributor.authorVilarino-Varlela, M
dc.contributor.authorElander, NO
dc.contributor.authorMcMenemin, R
dc.contributor.authorPickering, LM
dc.contributor.authorFaust, G
dc.contributor.authorChauhan, S
dc.contributor.authorJackson, RJ
dc.date.accessioned2017-03-01T12:06:07Z
dc.date.issued2017-03
dc.identifier.citationInternational journal of oncology, 2017, 50 (3), pp. 768 - 772
dc.identifier.issn1019-6439
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/433
dc.identifier.eissn1791-2423
dc.identifier.doi10.3892/ijo.2017.3847
dc.description.abstractThere is no standard of care in the UK or Ireland for second-line chemotherapy for patients with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients who have failed a platinum-based regimen, and is standard of care in Europe but is not routinely available in the UK. Data were collected retrospectively on patients who received vinfluine as a second-line treatment. The aims were to document the toxicity and efficacy in a real life setting. Data were collected on 49 patients from 9 sites across the UK and Ireland [median age, 64 (IQR, 57-70) years, 33 males]. All patients had advanced metastatic TCCU. Thirteen patients had bone or liver metastases, 4 patients had PS 2 and 11 patients had HB <10. Median vinflunine administration was 3.5 cycles (range 1-18). Most common grade 3-4 toxicities were constipation (4 patients) and fatigue (3 patients). Partial response rate was 29% (14 PR, 11 SD, 19 PD, 4 NE, 1 not available). Median OS was 9.1 (6.0, 12.7) months. Results are consistent with real life data from Europe. Toxicity is further reduced with prophylactic laxative and oral antibiotics. Vinflunine is an efficient and tolerable second line treatment in advanced TCCU.
dc.formatPrint-Electronic
dc.format.extent768 - 772
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectUrothelium
dc.subjectHumans
dc.subjectCarcinoma, Transitional Cell
dc.subjectBone Neoplasms
dc.subjectLiver Neoplasms
dc.subjectVinblastine
dc.subjectAntineoplastic Agents, Phytogenic
dc.subjectDisease-Free Survival
dc.subjectTreatment Outcome
dc.subjectRetrospective Studies
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectIreland
dc.subjectFemale
dc.subjectMale
dc.subjectUrinary Bladder Neoplasms
dc.subjectUnited Kingdom
dc.titleVICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.
dc.typeJournal Article
dcterms.dateAccepted2016-11-14
rioxxterms.versionofrecord10.3892/ijo.2017.3847
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2017-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfInternational journal of oncology
pubs.issue3
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublished
pubs.volume50
pubs.embargo.termsNo embargo
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0